<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778776</url>
  </required_header>
  <id_info>
    <org_study_id>CUCS-INTEC-MV-HBP-001</org_study_id>
    <nct_id>NCT02778776</nct_id>
  </id_info>
  <brief_title>Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome</brief_title>
  <official_title>Effect of Administration of Combination Metformine/Inulin Versus Metformine on Patients With Prostate Benign Hyperplasia and Metabolic Syndrome Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Ciencias de la Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitario de Ciencias de la Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus, insulin resistance, visceral obesity and disorders of lipid
      metabolism, especially triglyceride and hypertension are metabolic disorders that play a
      central role in pathophysiology of metabolic syndrome, and ultimately, the cardiovascular
      morbidity and mortality associated with atherosclerosis, such as myocardial infarction,
      cerebral vascular events, vascular dementia, heart failure and end stage renal disease.
      Recently other complications related with hyperinsulinemia like the prostate benign
      hypertrophy (BPH). Metformin is the treatment of choice in patients with metabolic syndrome,
      given its low cost and comparable pharmacological effects to the tiazolinedionas (eg
      pioglitazone), decreasing hyperinsulinemia, insulin resistance, concentration of free fatty
      acids and triglycerides, also it produces moderate weight loss, improving the metabolic
      profile triglcerides atherogenic lipid and carbohydrate and delaying the onset of diabetes
      mellitus in individuals with impaired fasting glucose.

      A second option for risk reduction would be the addition of inulin fiber type as it has been
      demonstrated some metabolic effects on benefices lipid metabolism and carbohydrate.

      It is expected that combination of metformin with inulin produce a beneficial effect through
      farmacological synergism and the impact on fisiopatological changes of metabolic syndrome
      that potentially is considered as an important risk factor for prostate growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to evaluate the effect of the combination of metformin / inulin on
      clinical, urodynamic parameters as well as metabolic and inflammatory profile in patients
      with benign prostate hypertrophy and metabolic syndrome.

      The investigators conducted a double-blind trial, randomized, on 4 groups, each group with 15
      male and female patients of 40 to 80 years of age with METS diagnosed by IDF criteria and
      clinical diagnose of HBP. Randomization will determine who will receive the intervention
      during 12 week trial, each group will be like:

      Group (A) intervention with combination metformin/ inulin: 15 individuals recieved
      combination of metformin/ agave inulin in a dosis of 500 mg / 10 grs per 24hrs during 12
      weeks.

      Group (B) Metformin plus Placebo of agave inulin: 15 individuals recieved Metformin in a
      dosis of 500mg per day (with the first bite of the second meal) plus homologue placebo of
      agave inulin (calcinated magnesia) in a dosis of 10grs each 24 hrs during 12 weeks.

      Group (C) agave inulin plus placebo of Metformin: 15 indivuduals recieved agave inulin in a
      dosis of 10grs per 24hrs plus homologate placebo of metformin (calcinated magnesia) in a
      dosis of 500 mg per day (with the first bite of the second meal) during 12 weeks.

      Group (D) Placebo of agave inulin plus Placebo of Metformin: homologate placebo of agave
      inulin (calcinated magnesia) in a dosis of 10 grs each 24 hrs plus homologate placebo of
      metformin (calcinated magnesia capsules) in a dosis of 500 mg per day (with the first bite of
      the second meal) during 12 weeks.

      The clinical findings and laboratory test include a metabolic profile and biosafety, will be
      baseline and at 12 weeks.

      Clinical components of Mets like antropometrics parameters, fasting glucose, fasting insulin,
      blood lipids, clinical finding of HBP and inflammation parameters and adipocitocins, IGF-1,
      insulin, prostatic specific antigen. Adverse events and adherence to treatment will be
      documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is
      considered with significance at p&lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (I-PSS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>before and after intervention questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured with a non elastic tape at baseline and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of body mass index</measure>
    <time_frame>12 weeks</time_frame>
    <description>before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer TBF-215 - Tanita)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Peripheral systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention using a digital sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Peripheral diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention using a digital sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HOMA-IR from base line to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention by using the formula for the homeostasis model assessment β-cell function index: 20 x fasting insulin (µU/Ml)/fasting glucose (mmol/L) - 3.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in High-density lipoprotein cholesterol at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglycerides at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total cholesterol at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting plasma glucose at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Before and after intervention by glucose oxidase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>qmax urine flow rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>before and after intervention by uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate serum antigen</measure>
    <time_frame>12 weeks</time_frame>
    <description>before and after intervention by colorimetry</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Agave inulin + Metfomin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Placebo of agave inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Agave Inulin+Placebo of Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Inulin + Placebo of Metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metfomin in tablet presentation of 500 mg</description>
    <arm_group_label>Agave inulin + Metfomin</arm_group_label>
    <arm_group_label>Metformin + Placebo of agave inulin</arm_group_label>
    <other_name>GLUCOPHAGE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Agave inulin</intervention_name>
    <description>Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.</description>
    <arm_group_label>Agave inulin + Metfomin</arm_group_label>
    <arm_group_label>Agave Inulin+Placebo of Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo of agave inulin</intervention_name>
    <description>Calcinated magnesia powder</description>
    <arm_group_label>Metformin + Placebo of agave inulin</arm_group_label>
    <arm_group_label>Placebo of Inulin + Placebo of Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metformin placebo</intervention_name>
    <description>Calcinated magnesia tablet</description>
    <arm_group_label>Agave Inulin+Placebo of Metformin</arm_group_label>
    <arm_group_label>Placebo of Inulin + Placebo of Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of metabolic syndrome by IDF criteria

               -  a person to be defined as having the metabolic syndrome they must have: Central
                  obesity (defined as waist circumference* with ethnicity specific values) ≥80 cm
                  in females and ≥90 cm in males; and plus any two of the following four factors:

               -  Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this
                  lipid abnormality Reduced HDL cholesterol

               -  &lt; 40 mg/dL (1.03 mmol/L) in males &lt; 50 mg/dL (1.29 mmol/L) in females or specific
                  treatment for this lipid abnormality

               -  Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment
                  of previously diagnosed hypertension

               -  Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously
                  diagnosed type 2 diabetes

          -  Age ranging from 40 to 80 years old

          -  Male patients

          -  Informed written consent

        Exclusion Criteria:

          -  Kidney disease

          -  Hepatic disease

          -  Thyroid disease

          -  Diabetes mellitus

          -  Ischemic heart disease

          -  Drug consumption

          -  Alcohol consumption of more than 2 ounces daily

          -  Consumption of drugs that intervene with lipid or glucose metabolism 2 months before

          -  Blood pressure &gt;160/100mmHg.

          -  Lack of adherence to treatment (adherence &lt;80%)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FERNANDO GROVER, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco, México</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Ciencias de la Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Grover Paez</investigator_full_name>
    <investigator_title>Fernando Grover-Paez, PhD</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Agave Inulin</keyword>
  <keyword>METS</keyword>
  <keyword>Inflammation parameters</keyword>
  <keyword>Urodynamic parameters</keyword>
  <keyword>Prostate hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

